Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms

Journal of Cell Biology

Volumn 202, Issue 7, 2013, Pages 1123-1138

  Xu, Qiaoqiao ^a,b,c   Huang, Shanshan ^b   Song, Mingke ^b   Wang, Chuan En ^b   Yan, Sen ^b   Liu, Xudong ^c   Gaertig, Marta A ^b   Yu, Shan Ping ^b   Li, He ^a   Li, Shihua ^b   Li, Xiao Jiang ^b,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; HUNTINGTIN; POLYGLUTAMINE; SYNAPSIN I; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN REGION; BRAIN TISSUE; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DEATH; DISEASE COURSE; EMBRYO; EXCITATORY POSTSYNAPTIC POTENTIAL; EXON; HIPPOCAMPUS; IMMUNOPRECIPITATION; INHIBITION KINETICS; LONG TERM POTENTIATION; MASS SPECTROMETRY; MOUSE; NEUROLOGIC DISEASE; NEUROTRANSMITTER RELEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION; SYNAPTOSOME; TRANSGENIC MOUSE; WESTERN BLOTTING;

AGE FACTORS; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN; CHROMATOGRAPHY, LIQUID; DOPAMINE; EXONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEURONS; PEPTIDES; PHOSPHORYLATION; PRESYNAPTIC TERMINALS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNAPSINS; SYNAPTIC TRANSMISSION; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TANDEM MASS SPECTROMETRY;

EID: 84886931430     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201303146     Document Type: Article

References (55)

1. Bibb, J.A., Z. Yan, P. Svenningsson, G.L. Snyder, V.A. Pieribone, A. Horiuchi, A.C. Nairn, A. Messer, and P. Greengard. 2000. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. USA. 97:6809-6814. http://dx.doi.org/10.1073/pnas.120166397
2. Borrell-Pagès, M., D. Zala, S. Humbert, and F. Saudou. 2006. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 63:2642-2660. http://dx.doi.org/10.1007/s00018-006-6242-0
3. Cummings, D.M., C. Cepeda, and M.S. Levine. 2010. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro. 2:147-156. http://dx.doi.org/10.1042/AN20100007
4. Davies, S.W., M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, C.A. Ross, E. Scherzinger, E.E. Wanker, L. Mangiarini, and G.P. Bates. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:537-548. http://dx.doi.org/10.1016/S0092-8674(00)80513-9
5. Deckel, A.W., A. Gordinier, D. Nuttal, V. Tang, C. Kuwada, R. Freitas, and K.A. Gary. 2001. Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res. 919:70-81. http://dx.doi.org/10.1016/S0006-8993(01)03000-1
6. DiFiglia, M., E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1990-1993. http://dx.doi.org/10.1126/science.277.5334.1990
7. Fornasiero, E.F., D. Bonanomi, F. Benfenati, and F. Valtorta. 2010. The role of synapsins in neuronal development. Cell. Mol. Life Sci. 67:1383-1396. http://dx.doi.org/10.1007/s00018-009-0227-8
8. Fusco, F.R., S. Anzilotti, C. Giampà, C. Dato, D. Laurenti, A. Leuti, L. Colucci D'Amato, L. Perrone, G. Bernardi, and M.A. Melone. 2012. Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition. Neurobiol. Dis. 46:225-233. http://dx.doi.org/10.1016/j.nbd.2012.01.011
9. Garden, G.A., and A.R. La Spada. 2012. Intercellular (mis)communication in neurodegenerative disease. Neuron. 73:886-901. http://dx.doi.org/10.1016/j.neuron.2012.02.017
10. Giralt, A., A. Saavedra, O. Carretón, X. Xifró, J. Alberch, and E. Pérez-Navarro. 2011. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum. Mol. Genet. 20:4232-4247. http://dx.doi.org/10.1093/hmg/ddr351
11. Gray, M., D.I. Shirasaki, C. Cepeda, V.M. André, B. Wilburn, X.H. Lu, J. Tao, I. Yamazaki, S.H. Li, Y.E. Sun, et al. 2008. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28:6182-6195. http://dx.doi.org/10.1523/JNEUROSCI.0857-08.2008
12. Gu, X., E.R. Greiner, R. Mishra, R. Kodali, A. Osmand, S. Finkbeiner, J.S. Steffan, L.M. Thompson, R. Wetzel, and X.W. Yang. 2009a. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron. 64:828-840. http://dx.doi.org/10.1016/j.neuron.2009.11.020
13. Gu, Z., W. Liu, and Z. Yan. 2009b. beta-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J. Biol. Chem. 284:10639-10649. http://dx.doi.org/10.1074/jbc. M806508200
14. Gutekunst, C.A., S.H. Li, H. Yi, J.S. Mulroy, S. Kuemmerle, R. Jones, D. Rye, R.J. Ferrante, S.M. Hersch, and X.J. Li. 1999. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19:2522-2534.
15. Heng, M.Y., P.J. Detloff, and R.L. Albin. 2008. Rodent genetic models of Huntington disease. Neurobiol. Dis. 32:1-9. http://dx.doi.org/10.1016/j.nbd.2008.06.005
16. Iwata, S.I., G.H. Hewlett, S.T. Ferrell, L. Kantor, and M.E. Gnegy. 1997. Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine. J. Pharmacol. Exp. Ther. 283:1445-1452.
17. Joshi, P.R., N.P. Wu, V.M. André, D.M. Cummings, C. Cepeda, J.A. Joyce, J.B. Carroll, B.R. Leavitt, M.R. Hayden, M.S. Levine, and N.S. Bamford. 2009. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 29:2414-2427. http://dx.doi.org/10.1523/JNEUROSCI.5687-08.2009
18. Kaltenbach, L.S., E. Romero, R.R. Becklin, R. Chettier, R. Bell, A. Phansalkar, A. Strand, C. Torcassi, J. Savage, A. Hurlburt, et al. 2007. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 3:e82. http://dx.doi.org/10.1371/journal.pgen.0030082
19. Kim, M.W., Y. Chelliah, S.W. Kim, Z. Otwinowski, and I. Bezprozvanny. 2009. Secondary structure of Huntingtin amino-terminal region. Structure. 17: 1205-1212. http://dx.doi.org/10.1016/j.str.2009.08.002
20. Landles, C., K. Sathasivam, A. Weiss, B. Woodman, H. Moffitt, S. Finkbeiner, B. Sun, J. Gafni, L.M. Ellerby, Y. Trottier, et al. 2010. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 285:8808-8823. http://dx.doi.org/10.1074/jbc. M109.075028
21. Li, H., T. Wyman, Z.X. Yu, S.H. Li, and X.J. Li. 2003. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum. Mol. Genet. 12:2021-2030. http://dx.doi.org/10.1093/hmg/ddg218
22. Li, S., and X.J. Li. 2006. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol. Neurodegener. 1:19. http://dx.doi.org/10.1186/1750-1326-1-19
23. Li, S.H., A.L. Cheng, H. Li, and X.J. Li. 1999. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J. Neurosci. 19:5159-5172.
24. Li, S.H., A.L. Cheng, H. Zhou, S. Lam, M. Rao, H. Li, and X.J. Li. 2002. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22:1277-1287. http://dx.doi.org/10.1128/MCB.22.5.1277-1287.2002
25. Li, X.J., and S. Li. 2011. Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 43:4-8. http://dx.doi.org/10.1016/j.nbd.2010.11.018
26. Liévens, J.C., B. Woodman, A. Mahal, and G.P. Bates. 2002. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol. Cell. Neurosci. 20: 638-648. http://dx.doi.org/10.1006/mcne.2002.1152
27. Maat-Schieman, M., R. Roos, M. Losekoot, J. Dorsman, C. Welling-Graafland, I. Hegeman-Kleinn, F. Broeyer, M. Breuning, and S. van Duinen. 2007. Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease. Brain Pathol. 17:31-37. http://dx.doi.org/10.1111/j.1750-3639.2006.00040.x
28. Maneuf, Y.P., and A.T. McKnight. 2001. Calcitonin gene-related peptidemediated increase in K(+)-induced [(3)H]-dopamine release from rat caudal striatal slices. Neurosci. Lett. 310:73-76. http://dx.doi.org/10.1016/S0304-3940(01)02056-0
29. Menalled, L.B., and M.F. Chesselet. 2002. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23:32-39. http://dx.doi.org/10.1016/S0165-6147(00)01884-8
30. Menalled, L.B., J.D. Sison, Y. Wu, M. Olivieri, X.J. Li, H. Li, S. Zeitlin, and M.F. Chesselet. 2002. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 22:8266-8276.
31. Milnerwood, A.J., and L.A. Raymond. 2010. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 33:513-523. http://dx.doi.org/10.1016/j.tins.2010.08.002
32. Mohamad, O., M. Song, L. Wei, and S.P. Yu. 2013. Regulatory roles of the NMDA receptor GluN3A subunit in locomotion, pain perception and cognitive functions in adult mice. J. Physiol. 591:149-168. http://dx.doi.org/10.1113/jphysiol.2012.239251
33. Orr, H.T., and H.Y. Zoghbi. 2007. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30:575-621. http://dx.doi.org/10.1146/annurev.neuro.29.051605.113042
34. Patel, D.R., A.M. Young, and M.J. Croucher. 2001. Presynaptic alpha-amino- 3-hydroxy-5-methyl-4-isoxazole propionate receptor-mediated stimulation of glutamate and GABA release in the rat striatum in vivo: a dual-label microdialysis study. Neuroscience. 102:101-111. http://dx.doi.org/10.1016/S0306-4522(00)00463-2
35. Pekny, M., and M. Nilsson. 2005. Astrocyte activation and reactive gliosis. Glia. 50:427-434. http://dx.doi.org/10.1002/glia.20207
36. Ren, X., and J.H. Hurley. 2011. Proline-rich regions and motifs in trafficking: from ESCRT interaction to viral exploitation. Traffic. 12:1282-1290. http://dx.doi.org/10.1111/j.1600-0854.2011.01208.x
37. Rizo, J., and T.C. Südhof. 2002. Snares and Munc18 in synaptic vesicle fusion. Nat. Rev. Neurosci. 3:641-653.
38. Ross, C.A., and S.J. Tabrizi. 2011. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10:83-98. http://dx.doi.org/10.1016/S1474-4422(10)70245-3
39. Sathasivam, K., A. Neueder, T.A. Gipson, C. Landles, A.C. Benjamin, M.K. Bondulich, D.L. Smith, R.L. Faull, R.A. Roos, D. Howland, et al. 2013. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. USA. 110:2366-2370. http://dx.doi.org/10.1073/pnas.1221891110
40. Schilling, G., M.W. Becher, A.H. Sharp, H.A. Jinnah, K. Duan, J.A. Kotzuk, H.H. Slunt, T. Ratovitski, J.K. Cooper, N.A. Jenkins, et al. 1999. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:397-407. http://dx.doi.org/10.1093/hmg/8.3.397
41. Schweitzer, E.S., M.J. Sanderson, and C.G. Wasterlain. 1995. Inhibition of regulated catecholamine secretion from PC12 cells by the Ca2+/calmodulin kinase II inhibitor KN-62. J. Cell Sci. 108:2619-2628.
42. Shirasaki, D.I., E.R. Greiner, I. Al-Ramahi, M. Gray, P. Boontheung, D.H. Geschwind, J. Botas, G. Coppola, S. Horvath, J.A. Loo, and X.W. Yang. 2012. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron. 75:41-57. http://dx.doi.org/10.1016/j.neuron.2012.05.024
43. Shupliakov, O., V. Haucke, and A. Pechstein. 2011. How synapsin I may cluster synaptic vesicles. Semin. Cell Dev. Biol. 22:393-399. http://dx.doi.org/10.1016/j.semcdb.2011.07.006
44. Slow, E.J., J. van Raamsdonk, D. Rogers, S.H. Coleman, R.K. Graham, Y. Deng, R. Oh, N. Bissada, S.M. Hossain, Y.Z. Yang, et al. 2003. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12:1555-1567. http://dx.doi.org/10.1093/hmg/ddg169
45. Smith, R., P. Brundin, and J.Y. Li. 2005. Synaptic dysfunction in Huntington's disease: a new perspective. Cell. Mol. Life Sci. 62:1901-1912. http://dx.doi.org/10.1007/s00018-005-5084-5
46. Steiner, J.P., T.M. Dawson, M. Fotuhi, and S.H. Snyder. 1996. Immunophilin regulation of neurotransmitter release. Mol. Med. 2:325-333.
47. Suopanki, J., C. Götz, G. Lutsch, J. Schiller, P. Harjes, A. Herrmann, and E.E. Wanker. 2006. Interaction of huntingtin fragments with brain membranes- clues to early dysfunction in Huntington's disease. J. Neurochem. 96: 870-884. http://dx.doi.org/10.1111/j.1471-4159.2005.03620.x
48. Tebbenkamp, A.T., D. Swing, L. Tessarollo, and D.R. Borchelt. 2011. Premature death and neurologic abnormalities in transgenic mice expressing a mutant huntingtin exon-2 fragment. Hum. Mol. Genet. 20:1633-1642. http://dx.doi.org/10.1093/hmg/ddr040
49. Thompson, L.M., C.T. Aiken, L.S. Kaltenbach, N. Agrawal, K. Illes, A. Khoshnan, M. Martinez-Vincente, M. Arrasate, J.G. O'Rourke, H. Khashwji, et al. 2009. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187:1083-1099. http://dx.doi.org/10.1083/jcb.200909067
50. Truant, R., R. Atwal, and A. Burtnik. 2006. Hypothesis: Huntingtin may function in membrane association and vesicular trafficking. Biochem. Cell Biol. 84:912-917. http://dx.doi.org/10.1139/o06-181
51. Vonsattel, J.P., and M. DiFiglia. 1998. Huntington disease. J. Neuropathol. Exp. Neurol. 57:369-384. http://dx.doi.org/10.1097/00005072-199805000-00001
52. Wang, C.E., H. Zhou, J.R. McGuire, V. Cerullo, B. Lee, S.H. Li, and X.J. Li. 2008. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol. 181:803-816. http://dx.doi.org/10.1083/jcb.200710158
53. Wishart, T.M., S.H. Parson, and T.H. Gillingwater. 2006. Synaptic vulnerability in neurodegenerative disease. J. Neuropathol. Exp. Neurol. 65:733-739. http://dx.doi.org/10.1097/01.jnen.0000228202.35163.c4
54. Woodman, B., R. Butler, C. Landles, M.K. Lupton, J. Tse, E. Hockly, H. Moffitt, K. Sathasivam, and G.P. Bates. 2007. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 72:83-97. http://dx.doi.org/10.1016/j.brainresbull.2006.11.004
55. Zhou, H., F. Cao, Z. Wang, Z.X. Yu, H.P. Nguyen, J. Evans, S.H. Li, and X.J. Li. 2003. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J. Cell Biol. 163:109-118. http://dx.doi.org/10.1083/jcb.200306038